BridgeBio Pharma BBIO Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.
The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about BridgeBio Pharma's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BridgeBio Pharma's cash & equivalents?
- BridgeBio Pharma (BBIO) reported cash & equivalents of $882.02M in Q1 2026.
- How has BridgeBio Pharma's cash & equivalents changed year-over-year?
- BridgeBio Pharma's cash & equivalents increased by 62.5% year-over-year, from $542.74M to $882.02M.
- What is the long-term trend for BridgeBio Pharma's cash & equivalents?
- Over 5 years (2020 to 2025), BridgeBio Pharma's cash & equivalents has grown at a -13.7% compound annual growth rate (CAGR), from $356.08M to $170.49M.
- What does cash & equivalents mean?
- The total amount of cash and highly liquid assets the company has available for immediate use.
- How do you interpret cash & equivalents?
- An increase suggests improved liquidity and financial runway, while a decrease may indicate high cash burn from R&D or operational needs.
- How does cash & equivalents compare across companies?
- Biotech companies typically maintain high cash balances to support multi-year clinical trial cycles compared to mature manufacturing firms.